As Critical As They Are Different: Can Over 270 Medicines Fit Into The ONE Critical Medicines Act?
This video highlights the vital role of plasma-derived medicines and the need to strengthen Europe’s plasma supply chain. Unlike lab-made medicines, these therapies depend on donations from individuals worldwide, making their production complex and vulnerable.
Speakers emphasise the essential role of these treatments for patients, the importance of raising awareness and representing patients in EU-level discussions, and the potential of the EU Critical Medicines Act to improve plasma collection and access to therapy. The discussion underlines the need for collaboration between industry, physicians and patients, and the importance of recognising the unique attributes of plasma-derived medicines to ensure that patients receive the right treatment at the right time.
